Kristina Burrow

FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA.

YourBio Health, Inc. develops health monitoring products. It is developing an array of products based on the company's proprietary TAP? (Touch Activated Phlebotomy) painless blood collection platform. The company was founded by Richard Rox Anderson, Joerg Lahann, Robert S. Langer Jr., Douglas A. Levinson and Samir Mitragotri in 2008 and is headquartered in Medford, MA.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Bowdoin College is an independent, nonsectarian, coeducational residential, undergraduate liberal arts institution founded in 1794. It is located in Brunswick, ME.

California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA.

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco.

Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa.

Foresite Capital Management LLC (Foresite Capital) is a private equity firm founded in 2010 by James Tananbaum. The firm is headquartered in San Francisco.

Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA.

Jnana Therapeutics, Inc. provides drug development services. The firm focuses on immunometabolism changing the metabolic pathways in immune cells to affect function; lysosomal function and mucosal defense. The company was founded by Stuart L. Schreiber, Ramnik Xavier, Joanne Kotz and Joel C. Barrish and is headquartered in Boston, MA.

Newpath Management LP (Newpath Management) is a venture capital firm founded in 2018 by Daniel Yadegar and Thomas J. Cahill. The firm is headquartered in Boston, Massachusetts.

Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA.

Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA.

Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA.

Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA.

Kisbee Therapeutics, Inc develops novel therapeutic agents for neurodegenerative diseases. The company was founded by Benjamin Cravatt, Jennifer Lippincott Schwartz, Emily Ricqu and Stuart L.Schreiber and is headquartered in DE.

Kojin Therapeutics, Inc. operates as a small-molecule therapeutics company. It focuses on translating deep biological insight into the plasticity of human cell states to develop therapeutics for cancer, fibrosis, ischemia and immune modulation. The company was founded by Benjamin Cravatt, Stephanie K. Dougan and Stuart L.Schreiber and is headquartered in the United States.

Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland.

Part of Ikena Oncology, Inc., Amplify Medicines, Inc. develops pharmaceutical drugs. The company is based in Boston, MA. The company was founded by Peter Smith.

Foresite Life Sciences Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded in January 2021 and is headquartered in San Francisco, CA.

Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020.

Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021.

Part of Gilead Sciences, Inc., XinThera, Inc. is a drug discovery company focused on building a small molecule oncology and immunology pipeline. The company is based in San Diego, CA. XinThera is backed by a group of international investors including Foresite Capital, OrbiMed Advisors, LLC, and TTM Capital. XinThera's lead programs focus on well-validated targets with a mission to rapidly create and advance fast-follower programs with potential in areas of high-unmet need. XinThera was founded by Qing Dong, Stephen W. Kaldor, and Gene Hung. The CEO is Christopher C. LeMasters.

Belharra Therapeutics, Inc. is a drug discovery company that utilizes a unique photoaffinity-based chemoproteomics platform to identify novel small molecule drug candidates for previously difficult-to-treat diseases and conditions. The company is based in San Diego, CA, with its primary lab and offices located in the area. Belharra's proprietary discovery engine allows for the identification of small molecule starting points for drug development on any protein, in any conformational state, and in any cell type. The company was founded in 2021 by John Teijaro, Christopher G. Parker, Stuart L. Schreiber, and Benjamin F. Cravatt, and has since been led by CEO Jeffrey Jonker.

Nvelop Therapeutics, Inc. provides staffing services. The American company was founded by David Liu, J. Keith Joung. The CEO is Thomas J. Cahill.